Edwards' Full Euro Launch Of Sapien XT Valve Helps Boost Numbers
This article was originally published in The Gray Sheet
The European launch of Edwards Lifesciences' Sapien XT transcatheter valve drove a healthy jump in second-quarter revenue
You may also be interested in...
Following well-received one-year results from its PARTNER study, Edwards announced Sept. 23 that it has finally received FDA go-ahead to begin the U.S. pivotal trial of its next-generation Sapien XT transcatheter valve.
Data from multiple registries presented last week at the EuroPCR conference in Paris offered no major trouble spots for European cardiologists looking to expand use of transcatheter aortic heart valves and U.S. doctors anxiously awaiting their approval
Growth in Edwards Lifesciences surgical heart valve sales slowed in the first quarter due in part to pricing missteps, while the firm's nascent transcatheter heart valve business continued to pick up steam